Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Revenues:
Net sales	$ 21,998	$ 34,508	$ 39,035
Royalties	6,314,959	2,320,729	1,271,597
Licensing revenue	5,012,102	3,026,111	1,565,125
Consulting fees	46,667	280,000	280,000
Total revenues	11,395,726	5,661,348	3,155,757
Costs and expenses:
Research and development	972,078	1,223,931	488,646
General and administrative	5,231,881	6,470,449	4,832,019
Total costs and expenses	6,203,959	7,694,380	5,320,665
Operating income (loss)	5,191,767	(2,033,032)	(2,164,908)
Other income (expense):
Interest income	55,780	86,310	55,693
Interest expense	0	0	(39)
Other	15,823	13,130	(8,863)
Qualifying Therapeutic Discovery Grant	0	426,403	0
Total other income (expenses)	71,603	525,843	46,791
Income (loss) before benefit (expense) for income tax	5,263,370	(1,507,189)	(2,118,117)
Income tax benefit (expense)	1,338,256	(1,351)	161,574
Net income (loss)	$ 6,601,626	$ (1,508,540)	$ (1,956,543)
Basic net income (loss) per share (in dollars per share)	$ 1.04	$ (0.24)	$ (0.32)
Diluted net income (loss) per share (in dollars per share)	$ 0.93	$ (0.24)	$ (0.32)
Shares used in computation of basic net income (loss) per share (in shares)	6,340,648	6,261,214	6,065,939
Shares used in computation of diluted net income (loss) per share (in shares)	7,107,134	6,261,214	6,065,939